biote Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $40.6M
- Price
- $1.34
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.19%
- Volume
- 110.8K
About
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
Quick stats
Shares outstanding30.3M
Computed float22.9M
Float / shares75.7%
Key info
SectorHealthcare
IndustryMedical - Care Facilities
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001819253
Websitehttps://biote.com
AI Summary
AI-generated1/16
standardbearishearnings
Biote Reports Second Quarter 2026 Financial Results
Biote reported second quarter revenue of $44.2 million, a decrease of 9.5% year-over-year, and swung to a net loss of $7.4 million compared to net income of $3.9 million in the prior year.
The financial decline was primarily attributed to a voluntary product recall of hormone pellets shipped by Asteria Health, which negatively impacted procedure revenue and gross margins.
Management revised its full-year 2026 outlook, now expecting revenue above $175 million, and delayed the anticipated return to year-over-year procedure revenue growth due to the recall's lingering effects.
Red flags
- Swing from net income of $3.9M to net loss of $7.4M year-over-year
- Voluntary product recall impacting revenue and gross margins
- Revised full-year outlook delays return to year-over-year procedure revenue growth